Asset

  • No.

    127

  • Asset Title

    A First in Class Small Molecule as a Novel YB1 Inhibitor

  • Organization

    Oregon Health and Science University

  • Product Type

    Small molecule

  • Therapeutic Area

    Oncology

  • Development Stage

    Hit To Lead or Lead Optimization

  • Technical Summary

    • An azopodophyllotoxin small molecule, SU056, that potently inhibits tumor growth and progression via YB-1 inhibition. This YB-1 inhibitor inhibits cell proliferation, resistance to apoptosis in ovarian cancer (OC) cells, and arrests in the G1 phase. 

    • The development of resistance to chemotherapy treatment in solid tumors is associated with up-regulation of the DNA/RNA binding protein Y box binding protein 1 (YB-1) and a worsened prognosis for cancer patients. Inventors have developed a first-in-class small molecule inhibitor of YB-1 that synergizes with chemotherapy to reduce ovarian cancer progression and potentially patient mortality. 

    • Ovarian cancer has a high mortality rate, with frequent development of treatment resistance and disease relapse. YB-1 has a wellestablished role in cancer, increasing the stability of many oncogenic transcripts which are associated with disease progression and treatment resistance, and elevated YB-1 expression is associated with shorter term survival in ovarian cancer patients. 

    • Inventors have developed a novel inhibitor of YB-1 with validated efficacy in ovarian cancer models and the potential to improve outcomes in a broad range of cancers that demonstrate treatment resistance. 

  • Patent

    WO2022120242A1

  • Publication

    Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer. Cell Chem Biol (2021)

  • Attachment

TOP